In English | En español
Questions About Cancer? 1-800-4-CANCER

Breast Cancer Treatment (PDQ®)

  • Updated: 11/14/2014

Table 9. Adjuvant Systemic Treatment Options for Women With Axillary Node-Negative Breast Cancer

Patient Group Low Risk  Intermediate Risk High Risk 
Premenopausal, ER-positive or PR-positiveNone or tamoxifenTamoxifen plus chemotherapy, tamoxifen alone, ovarian ablation, GnRH analogaChemotherapy plus tamoxifen, chemotherapy plus ablation or GnRH analog*, chemotherapy plus tamoxifen plus ovarian ablation or GnRH*, or ovarian ablation alone or with tamoxifen or GnRH alone or with tamoxifen
Premenopausal, ER-negative or PR-negativeChemotherapy
Postmenopausal, ER-positive or PR-positiveNone or upfront AI or tamoxifen followed by AIUpfront AI or tamoxifen followed by AI +/- chemotherapyUpfront AI or tamoxifen followed by AI +/- chemotherapy
Postmenopausal, ER-negative or PR-negativeChemotherapy

AI = aromatase inhibitor; ER = estrogen receptor; GnRH = gonadotropin-releasing hormone; PR = progesterone receptor
aNote: This treatment option is under clinical evaluation.